South Korean biotech shares in turnaround mode Companies in the IPO pipeline find it difficult to set prices
Translated by Kim So-in 공개 2019-10-28 08:00:00
이 기사는 2019년 10월 28일 08:00 thebell 에 표출된 기사입니다.
South Korean biotechnology companies that lost almost half the value in the second half of the year are beginning to gain ground while worries on sudden turnaround linger in the stock market.The country's biotechnology shares have been on a roller-coaster over the last few months. Some shares have surged almost ten times since August.
The turnaround was led by HLB. After announcing its top-line results in June, HLB's shares plummeted to 20 thousand won in August. However the company's stocks have been rallying with HLB reaffirming the successful trial result and the company's likely pre-new drug application meeting with U.S. Food and Drug Administration on October 24. The Kosdaq-listed HLB's shares exceeded 180 thousand won and the market capitalization which was under one trillion won increased to seven trillion won. Now HLB is threatening to unseat Celltrion, the largest company on Kosdaq by market capitalization.
Shares of other biotechnology companies that are conducting phase three clinical trials such as SillaJen and Helixmith also have recovered ground.
The recent share price movement of companies conducting phase three clinical trials are affecting biotechnology firms on the Kosdaq market. Valuations of biotechnology companies, which have suffered in the second half of the year, are rising again. In addition, the fact that shares of U.S.-based Biogen soared also boosted domestic biotechnology stocks. Biogen recently surprised investors by saying its Alzheimer's treatment was ready to start the regulatory approval process.
On the other hand, South Korean biotechnology companies that are in the initial public offering (IPO) pipeline by the end of the year feel uncomfortable with current movement. Jetema and TiumBio submitted securities registration statements and book-building process is around the corner. Medpacto and NovMetaPharma passed preliminary examination and are adjusting the registration statement submission date.
Those companies all haven't set the IPO price yet. "As share prices of listed biotechnology companies rose rapidly, it becomes hard to set a price range. It would be easier to proceed with the listing procedure if the share prices were still low," said an unlisted biotechnology company official.
When stock valuations rocket, investor expect IPO prices to be lower to avoid risks of post-IPO falling stock price. Especially for companies who plan to submit securities registration statements, it is critical to value themselves appropriately amid rising share prices. If the companies set the price too high, they might fail to attract investor interests at the subscription process.
Experts expect Jetema and TiumBio's subscription results will likely serve as a litmus test for forthcoming IPOs. Both companies expect market capitalization of approximately 470 billion won at their listings. Jetema will conduct book-building process on October 30 and 31, while TiumBio will conduct it on November 5 and 6.
(By reporter Min Kyung-moon)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”